# Scientific Evaluation Framework for Ontology-Guided GNN Immune Cell Deconvolution

## Phase 1: Foundation Building (Priority 1 - Critical)

### 1.1 Protein-Protein Interaction Integration
**CRITICAL**: Replace correlation-based edges with biological networks

**Implementation Requirements:**
```julia
# Required: Replace current graph construction
# Current (inadequate):
k = min(10, n_genes - 1)  # Arbitrary correlation threshold

# Required (biologically grounded):
function create_ppi_graph(genes::Vector{String}, ppi_database::String="STRING")
    # Load STRING PPI network (confidence > 0.7)
    # Map gene symbols to protein IDs
    # Create edges based on validated interactions
    # Weight edges by interaction confidence
end
```

**Data Sources to Integrate:**
- STRING database (protein interactions, confidence > 0.7)
- BioGRID (curated interactions)
- IntAct (literature-curated)
- ImmPort (immune-specific interactions)

### 1.2 Real Data Integration Pipeline
**CRITICAL**: Validate with GSE22886 (reference) + GSE65136 (bulk + cytometry)

**Required Implementation:**
```julia
function load_validation_datasets()
    # GSE22886: Pure cell type references (training signatures)
    # GSE65136: Bulk samples with measured proportions (ground truth)
    # Cross-platform normalization
    # Gene symbol mapping between platforms
end
```

### 1.3 Immune Cell Ontology Integration
**CRITICAL**: Replace arbitrary hierarchies with Cell Ontology

**Required Mapping:**
```julia
function create_immune_ontology_graph()
    # Cell Ontology immune branch (CL:0000542)
    # Parent-child relationships as directed edges
    # Regulatory relationships (activates/inhibits)
    # Differentiation pathways
end
```

## Phase 2: Method Development (Priority 2)

### 2.1 Enhanced Feature Engineering
**Current Problem**: Single-dimensional gene features insufficient

**Required Implementation:**
```julia
function create_gene_features(gene::String, expression::Float64)
    features = [
        expression,                    # Raw expression
        log2(expression + 1),         # Log-transformed
        gene_variance_score,          # Cross-sample variability
        pathway_membership_vector,    # KEGG/Reactome pathways
        tf_binding_sites,            # Transcription factor targets
        immune_signature_scores      # ImmPort gene sets
    ]
    return features
end
```

### 2.2 Heterogeneous Graph Architecture
**Current Problem**: Inappropriate homogeneous graph structure

**Required Architecture:**
```julia
struct ImmuneHeteroGNN
    gene_encoder::Dense           # Gene expression -> embeddings
    cell_encoder::Dense          # Cell type -> embeddings
    ppi_conv::GraphConv          # Gene-gene interactions
    regulation_conv::GraphConv   # Cell-cell regulatory edges
    ontology_conv::GraphConv     # Hierarchical relationships
    fusion_layer::Attention     # Multi-scale integration
    proportion_decoder::Dense    # -> cell proportions
end
```

### 2.3 Biological Constraints Integration
**Current Problem**: No enforcement of biological validity

**Required Constraints:**
```julia
function apply_biological_constraints(proportions)
    # Non-negativity: proportions ≥ 0
    # Sum-to-one: Σ(proportions) = 1
    # Mutual exclusivity: contradictory cell types
    # Hierarchical consistency: parent >= sum(children)
end
```

## Phase 3: Evaluation Framework (Priority 1)

### 3.1 Multi-Level Validation Strategy

#### Level 1: Synthetic Validation (Baseline)
- **Perfect Linear Mixtures**: NNLS should achieve ~100%
- **Non-linear Mixtures**: Add interaction terms, GNN should outperform
- **Missing References**: Remove cell types, test discovery capability

#### Level 2: Real Data Validation (Primary)
- **GSE65136 with Cytometry**: Direct proportion comparison
- **Cross-platform Validation**: Train on GSE22886, test on other datasets
- **Disease Datasets**: Cancer, autoimmune conditions

#### Level 3: Biological Validation (Gold Standard)
- **Flow Cytometry Correlation**: r > 0.8 required for clinical relevance
- **Single-cell Validation**: scRNA-seq proportion estimation
- **Functional Validation**: Pathway enrichment in predicted cell types

### 3.2 Statistical Acceptance Criteria

#### Minimum Performance Thresholds:
```julia
acceptance_criteria = (
    correlation_vs_cytometry = 0.75,  # Clinically meaningful
    rmse_improvement = 0.05,          # vs best baseline
    novel_detection_precision = 0.80,  # Unknown cell types
    statistical_significance = 0.01    # Bonferroni corrected
)
```

#### Required Effect Sizes:
- **Cohen's d > 0.8**: Large effect vs linear methods
- **Practical Significance**: >10% RMSE improvement
- **Consistency**: Significant across ≥3 independent datasets

### 3.3 Biological Interpretability Requirements

#### Ontology Benefit Validation:
```julia
function validate_ontology_contribution()
    # Ablation study: GNN with/without ontology
    # Effect size must be > 0.5 Cohen's d
    # Biological relevance: enriched pathways in learned embeddings
    # Hierarchical consistency: parent-child proportion relationships
end
```

## Phase 4: Comparative Benchmarking

### 4.1 Required Baseline Comparisons
**CRITICAL**: Must outperform established methods

```julia
required_baselines = [
    "CIBERSORTx",           # Current gold standard
    "EPIC",                 # Established method
    "quanTIseq",           # Clinical application
    "xCell",               # 64 cell types
    "Linear_NNLS",         # Simple baseline
    "Random_Forest",       # ML baseline
    "Support_Vector_Regression"  # Non-linear baseline
]
```

### 4.2 Novel Capability Evaluation
**Unique GNN Advantages to Demonstrate:**

1. **Unknown Cell Type Detection**
   ```julia
   function test_novel_detection()
       # Hold out one cell type from training
       # Test ability to detect as "novel"
       # Precision/Recall for unknown populations
   end
   ```

2. **Regulatory Pattern Discovery**
   ```julia
   function analyze_learned_patterns()
       # Extract attention weights
       # Map to known regulatory pathways
       # Validate biological interpretability
   end
   ```

## Phase 5: Implementation Roadmap

### Week 1-2: Critical Infrastructure
- [ ] Integrate STRING PPI database
- [ ] Load GSE22886 + GSE65136 datasets
- [ ] Implement Cell Ontology mapping
- [ ] Fix GNN architecture (heterogeneous graph)

### Week 3-4: Feature Engineering
- [ ] Multi-dimensional gene features
- [ ] Immune pathway integration
- [ ] Biological constraint enforcement
- [ ] Proper loss functions

### Week 5-6: Validation Pipeline
- [ ] Cross-validation with real data
- [ ] Cytometry correlation analysis
- [ ] Baseline method implementation
- [ ] Statistical testing framework

### Week 7-8: Evaluation & Analysis
- [ ] Comprehensive benchmarking
- [ ] Biological interpretability analysis
- [ ] Unknown cell type detection testing
- [ ] Publication-quality results

## Success Criteria Summary

### Technical Success:
- **Real Data Performance**: r > 0.75 vs cytometry
- **Statistical Significance**: p < 0.01 vs best baseline
- **Effect Size**: Cohen's d > 0.8

### Biological Success:
- **Pathway Enrichment**: Learned patterns match known biology
- **Novel Detection**: Precision > 0.8 for unknown cell types
- **Interpretability**: Attention weights correlate with regulatory networks

### Practical Success:
- **Computational Efficiency**: <10x slower than linear methods
- **Scalability**: Works on 10,000+ gene datasets
- **Robustness**: Consistent across multiple datasets

## Risk Mitigation

### High-Risk Scenarios:
1. **GNN underperforms on real data**: Focus on feature engineering
2. **Ontology provides no benefit**: Validate biological mapping
3. **Computational complexity too high**: Implement efficient architectures
4. **No novel cell detection**: Adjust to proportion refinement only

### Contingency Plans:
- **Hybrid Models**: Combine linear + GNN predictions
- **Ensemble Methods**: Multiple GNN architectures
- **Transfer Learning**: Pre-trained embeddings from single-cell data
